ZA200904304B - Use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine for the preparation of a drug having a selective inhibition of muscarinic M1, M2 and M3 receptors - Google Patents

Use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine for the preparation of a drug having a selective inhibition of muscarinic M1, M2 and M3 receptors

Info

Publication number
ZA200904304B
ZA200904304B ZA200904304A ZA200904304A ZA200904304B ZA 200904304 B ZA200904304 B ZA 200904304B ZA 200904304 A ZA200904304 A ZA 200904304A ZA 200904304 A ZA200904304 A ZA 200904304A ZA 200904304 B ZA200904304 B ZA 200904304B
Authority
ZA
South Africa
Prior art keywords
muscarinic
azabicyclo
phenothiazine
ylmethyl
receptors
Prior art date
Application number
ZA200904304A
Other languages
English (en)
Inventor
Thierry Clerc
Jacky Tisne-Versailles
Christophe Przybylski
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of ZA200904304B publication Critical patent/ZA200904304B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200904304A 2006-12-28 2009-01-01 Use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine for the preparation of a drug having a selective inhibition of muscarinic M1, M2 and M3 receptors ZA200904304B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0656002A FR2910814B1 (fr) 2006-12-28 2006-12-28 Utilisation du 10-°(r3)-1-azabicyclo°2.2.2!oct-3-ylmethyl!-10h- phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1,2,3

Publications (1)

Publication Number Publication Date
ZA200904304B true ZA200904304B (en) 2010-06-30

Family

ID=37951872

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200904304A ZA200904304B (en) 2006-12-28 2009-01-01 Use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine for the preparation of a drug having a selective inhibition of muscarinic M1, M2 and M3 receptors

Country Status (22)

Country Link
US (1) US8143245B2 (xx)
EP (1) EP2124956A1 (xx)
JP (1) JP5564263B2 (xx)
KR (1) KR101465277B1 (xx)
CN (1) CN101573120B (xx)
AR (1) AR064714A1 (xx)
AU (1) AU2007341274B2 (xx)
BR (1) BRPI0720591A2 (xx)
CA (1) CA2674162A1 (xx)
FR (2) FR2910814B1 (xx)
HK (1) HK1133207A1 (xx)
IL (1) IL199557A (xx)
MA (1) MA31026B1 (xx)
MX (1) MX2009006950A (xx)
NO (1) NO20092654L (xx)
NZ (1) NZ577915A (xx)
RU (1) RU2449794C2 (xx)
TN (1) TN2009000257A1 (xx)
TW (1) TWI423806B (xx)
UA (1) UA98131C2 (xx)
WO (1) WO2008080924A1 (xx)
ZA (1) ZA200904304B (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015133989A (ja) * 2015-04-28 2015-07-27 重泉 達志 健康食品
KR101969263B1 (ko) 2018-07-16 2019-04-15 이상호 산소 챔버용 산소 공급 장치

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1173445B (it) * 1984-03-16 1987-06-24 Guidotti & C Spa Labor Agenti ad attivita' antibroncospastica e composizioni farmaceutiche che li contengono
IT1251161B (it) * 1991-08-07 1995-05-04 Derivati ammonio quaternari di (-) e (+)-3-(10 h-fenotiazin-10-ilmetil)-l-azabiciclo (2.2.2.)ottano e composizioni farmaceutiche che li contengono
AU6686700A (en) * 1999-08-23 2001-03-19 H. Lundbeck A/S Treatment of urinary incontinence
JP2005513080A (ja) * 2001-12-20 2005-05-12 フェムファーマ， インコーポレイテッド 薬物の膣送達

Also Published As

Publication number Publication date
KR101465277B1 (ko) 2014-11-27
US8143245B2 (en) 2012-03-27
RU2009128326A (ru) 2011-02-10
WO2008080924A1 (fr) 2008-07-10
RU2449794C2 (ru) 2012-05-10
MX2009006950A (es) 2009-07-14
NO20092654L (no) 2009-09-28
CN101573120B (zh) 2011-11-23
IL199557A (en) 2014-09-30
JP5564263B2 (ja) 2014-07-30
CA2674162A1 (fr) 2008-07-10
FR2953721A1 (fr) 2011-06-17
AU2007341274A1 (en) 2008-07-10
AR064714A1 (es) 2009-04-22
UA98131C2 (ru) 2012-04-25
BRPI0720591A2 (pt) 2014-02-25
FR2910814B1 (fr) 2011-06-17
KR20090103887A (ko) 2009-10-01
MA31026B1 (fr) 2009-12-01
TW200833331A (en) 2008-08-16
FR2910814A1 (fr) 2008-07-04
US20100063276A1 (en) 2010-03-11
AU2007341274B2 (en) 2012-09-20
NZ577915A (en) 2011-12-22
EP2124956A1 (fr) 2009-12-02
JP2010514730A (ja) 2010-05-06
HK1133207A1 (xx) 2010-03-19
TN2009000257A1 (fr) 2010-10-18
CN101573120A (zh) 2009-11-04
TWI423806B (zh) 2014-01-21

Similar Documents

Publication Publication Date Title
HK1137762A1 (en) 1, 4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
IL199015A0 (en) Quinuclidinol derivatives as muscarinic receptor antagonists
ZA200702772B (en) Quinuclidine derivatives and their use as muscarinic M3 receptor antagonists
WO2009016564A3 (en) 2-aza-bicyclo[3.3.0]octane derivatives
HUS1400056I1 (hu) Glükopiranozil-helyettesített benzol-származékok, az említett vegyületeket tartalmazó gyógyszerek, azok alkalmazása, és eljárás elõállításukra
ZA200704163B (en) Oral medicament for the modified release of at least one active principle, in a multimicrocapsule form
WO2008081399A3 (en) 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
ZA200801162B (en) Trazodone composition for once a day administration
IL194076A (en) Benzo Compounds - [d] - Imidzo [2, 1 – b] Thiazole-2-Ilphenyl for the Treatment of Illness
HK1128593A1 (en) A composition suitable for ophthalmic administration
EP2118656A4 (en) IMPROVED TEST PROCEDURE FOR IMMUNOSUPPRESSIVA
IL203738A (en) Use of 1- (2-Isopropoxyethyl) -2-Theoxo-1, 2, 3, 5-Tetrahydro-Pyrolo [3, 2-d] Pyrimidine-4-On or its Acceptable Pharmaceutical Salt for the Preparation of a Multi-Systemic Degenerative Drug
ZA200807321B (en) Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs
IL195857A0 (en) Pharmaceutical compositions for treating psychological conditions comprising muscarinic receptor m1 antagonists
IL195243A0 (en) Use of a fusion molecule for the preparation of a medicament for treating rheumatoid arthritis
EP1852117A4 (en) PHARMACEUTICAL AGENT COMPRISING SOLIFENACIN
IL197732A (en) A system for packaging intravenous pharmaceutical preparations and kits containing them
WO2008087123A3 (en) Use of 5-ht6 antagonists to prevent relapse into addiction
WO2007007282A3 (en) Azabicyclo derivatives as muscarinic receptor antagonists
ZA200904304B (en) Use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine for the preparation of a drug having a selective inhibition of muscarinic M1, M2 and M3 receptors
EP1992349B8 (de) CGRP-antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
IL222788A (en) Processes for the preparation of zilpatrol and its salts, zilpatrol and its salts prepared in these processes and their use in the preparation of a drug
EP1946759A4 (en) THERAPEUTIC AGENT AGAINST NAUSEUM AND / OR VOMITING
SI1641438T1 (sl) Postopek za pripravo amorfne oblike zdravila
ZA201005397B (en) 17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-one derivative,use thereof,and medicament containing said derivative